<DOC>
	<DOCNO>NCT02090400</DOCNO>
	<brief_summary>The aim study see change bone mineral density discontinuation stop use bisphosphonates make switch bazedoxifene ) .</brief_summary>
	<brief_title>Switching From Oral Bisphosphonates Bazedoxifene Evaluate Effects Bone Mineral Density Postmenopausal Women</brief_title>
	<detailed_description>The primary hypothesis : `` Comparing control group ( Calcium+VitD ) , Bazedoxifene group ( 20mg daily+ calcium+VitD ) efficient reduce BMD spine 12 month treatment . postmenopausal woman switch daily , weekly monthly bisphosphonates therapy . It non-inferiority study Bazedoxifene compare biphosphonates , patient control baseline . It superiority study Bazedoxifene compare Calcium+VitD . Taking account difference percentage change observe total BMD spine 12 month patient treat Bazedoxifene+Ca+VitD least 110 patient include , 55 arm treatment . This simple size go allow u detect difference percentage change observe total BMD spine 12 month two treatment arm , 0.25 % , significance level 95 % , 80 % power . It estimate standard deviation 0.5 % , 10 % lose follow-up rate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory postmenopausal woman 55 year old screening Have receive daily , weekly monthly oral bisphosphonates least 3 year treatment change indicate ( response bisphosphonates , bad tolerability potential risk side effect long term treatment bisphosphonatesindicated Federal Drug Administration , European Medicines Agency . Subjects stop bisphosphonates therapy one month screen visit subject daily weekly bisphosphonates Subjects stop bisphosphonates therapy two month screen visit subject monthly bisphosphonates Screening Tscore lumbar spine â‰¤ 2.0 4.0 Dual X ray Absorptiometry ( DXA ) scan At least 2 lumbar vertebra must evaluable DXA Al least one hip must evaluable DXA ( secondary objective ) Any disorder compromise ability subject give write informed consent and/or comply study procedure Current use medication prescribe osteoporosis oral bisphosphonates Subjects receive intravenous bisphosphonates fluoride ( except dental treatment ) Subjects receive Selective Estrogens Receptor Modulator ( SERM ) , anabolic steroid , systemic hormone replacement , calcitonin calcitriol within 3 month . Subjects receive strontium ranelate , parathyroid hormone ( PTH ) PTH derivates within 1 year . Hyper hypothyroidism , current hyper hypoparathyroidism History Venous Thromboembolism Event ( VTE ) Significantly impaired renal function determine estimate Glomerular Filtration Rate le 35 mL/min Hyper hypocalcemia Vitamin D deficiency ( serum 25 ( OH ) vit D level &lt; 20 ng/mL ( &lt; 50nmol/L ) Any condition could result impaired calcium metabolism metabolic bone disease could interfere interpretation finding</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Women</keyword>
	<keyword>Osteoporosis , Postmenopausal</keyword>
	<keyword>Bazedoxifene</keyword>
	<keyword>BMD</keyword>
</DOC>